Acquisitions - Narrative (Details) - USD ($) $ in Thousands			12 Months Ended
	May 30, 2024	Feb. 05, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Asset Acquisition [Line Items]
Research and development			$ 2,606,848	$ 1,627,594	$ 1,585,936
Escient
Asset Acquisition [Line Items]
Payments for asset acquisitions	$ 782,500
Asset acquisition, consideration transferred, transaction cost	2,500
Upfront payment	785,000
Asset acquisition, compensation expense			31,500
In-process research and development assets	679,388
Research and development			$ 679,400
Escient | In Process Research and Development - INCB000262
Asset Acquisition [Line Items]
In-process research and development assets	644,800
Escient | In Process Research and Development - INCB000547
Asset Acquisition [Line Items]
In-process research and development assets	$ 34,600
Maximum | Xencor
Asset Acquisition [Line Items]
Uncured material breach, written notice period (in days)		120 days
Payment obligation breach, written notice period (in days)		30 days
Minimum | Xencor
Asset Acquisition [Line Items]
Advance written notice period (in days)		90 days
Development and Regulatory Milestones | Maximum | Xencor
Asset Acquisition [Line Items]
Additional milestone payments under the license agreement		$ 186,500
Commercialization Milestones | Maximum | Xencor
Asset Acquisition [Line Items]
Additional milestone payments under the license agreement		$ 50,000
Expiration period (in years)		11 years
MorphoSys AG
Asset Acquisition [Line Items]
Payment to acquire license agreement		$ 25,000